Both bonds and gold have outperformed stocks over the last year. Our last breadth thrust indicator from early 2019 closes out profitably. Based upon its underweight status, I still think gold could shine. Biotech is also now underweight.
Complete the form and a member of our team will send you a copy of this publication.
While you wait, explore additional NDR research and solutions.
Institutional Investors
Custom Research
Wealth Managers
Stock Selection
ETF Selection
Please note that you are using an unsupported browser. While the site will continue to function, you might experience sub-optimal behavior until you upgrade. Please update your browser to a later version for a better experience.